رسالة جامعية
Validación de modelos de pronóstico en una cohorte colombiana de pacientes con mieloma múltiple: Un estudio con datos del mundo real ; Validation of Prognostic Models in a Colombian Cohort of Multiple Myeloma Patients: A RealWorld Data Study
| العنوان: | Validación de modelos de pronóstico en una cohorte colombiana de pacientes con mieloma múltiple: Un estudio con datos del mundo real ; Validation of Prognostic Models in a Colombian Cohort of Multiple Myeloma Patients: A RealWorld Data Study |
|---|---|
| المؤلفون: | Pedraza Morales, Julian Eduardo |
| المساهمون: | Villar Centeno, Luis Ángel, Abello Polo, Virginia, Villar Centeno, Luis Ángel 0000048488, Abello Polo, Virginia 0000744212, Villar Centeno, Luis Ángel es&oi=ao, Abello Polo, Virginia es&oi=ao, Pedraza Morales, Julian Eduardo 0000-0001-6744-2469, Abello Polo, Virginia 0000-0001-6507-4041 |
| بيانات النشر: | Universidad Autónoma de Bucaramanga UNAB Facultad Ciencias de la Salud Maestría en Métodos para la Producción y Aplicación de Conocimiento Científico en Salud |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | Medical sciences, Health sciences, Overall Survival (OS), Kaplan-Meier (KM), Discrimination, Calibration, Progression-free survival (PFS), International staging system (ISS), Risk model validation, Multiple myeloma (MM), National registry of hematological oncological diseases in Colombia (RENEHOC), Plasma cell diseases, Medical literature, Epidemiology, Neoplasms, Ciencias médicas, Enfermedades de las células plasmáticas, Literatura médica, Ciencias de la salud, Epidemiología, Neoplasmas, Mieloma múltiple (MM), Supervivencia global (SG), Supervivencia libre de progresión (SLP), Índice de Estadificación Internacional (ISS), Validación, Registro nacional de enfermedades hematológicas oncológicas en Colombia (RENEHOC), Modelos de riesgo, Discriminación, Calibración |
| جغرافية الموضوع: | Colombia, UNAB Campus Bucaramanga |
| الوقت: | 2022-2023 |
| الوصف: | Título: Validación de Modelos de Pronóstico en una Cohorte Colombiana de Pacientes con Mieloma Múltiple: Un Estudio con Datos del Mundo Real. Introducción: el mieloma múltiple (MM) es una enfermedad hematológica maligna que afecta a un número significativo de pacientes en Colombia y en todo el mundo. Para su estudio, el Registro Nacional de Enfermedades Hematológicas Oncológicas en Colombia (RENEHOC) recopila datos del mundo real de forma cooperativa con la participación de múltiples centros. La enfermedad presenta un pronóstico variable y se han identificado diversos factores de riesgo. Si bien, existen varios modelos de predicción para la supervivencia global (SG), como el International Staging System (ISS) y el Revised International Staging System (R-ISS), ampliamente reconocidos en las guías de manejo, aún falta una validación en el contexto local. Objetivo: En este estudio, se llevó a cabo un proceso de identificación de modelos de riesgo aplicables en la cohorte, seguido de una validación externa de los modelos identificados. Además, se describieron las características clínicas y citogenéticas, y se analizó la supervivencia de los pacientes con MM incluidos en el registro RENEHOC. Metodología: Los datos provienen de RENEHOC, una iniciativa que ha estado recopilando información de manera ambispectiva desde 2018, cuenta con la participación de 25 centros en 6 ciudades colombianas. Para identificar modelos de riesgo aplicables, se llevó a cabo una exhaustiva revisión de la literatura médica. Se definió la supervivencia global (SG) como la muerte por cualquier causa y la supervivencia libre de progresión (SLP) como un desenlace compuesto que incluye muerte por cualquier causa, recaída, progresión y cambio a terapia de segunda línea. Los análisis de supervivencia se realizaron utilizando el método de Kaplan-Meier (KM) y se estratificaron según los niveles de riesgo de los modelos bajo estudio. Para evaluar las diferencias entre los grupos de riesgo, se aplicó el test de Mantel-Cox log-Rank. En el proceso de ... |
| نوع الوثيقة: | master thesis |
| وصف الملف: | application/pdf |
| اللغة: | Spanish; Castilian |
| العلاقة: | Rajkumar SV. Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. 2018; Ludwig H, Bolejack V, Crowley J, Bladé J, San Miguel J, Kyle RA, et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. Journal of Clinical Oncology. 2010 Mar 20;28(9):1599–605.; Zhou L, Yu Q, Wei G, Wang L, Huang Y, Hu K, et al. Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. BMC Cancer [Internet]. 2021 Dec 1 [cited 2023 Jan 17];21(1):1–13. Available from: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-021-08280-yTest; Cuenta de alto costo. Cuenta de alto costo. 2022 [cited 2022 Sep 14]. SITUACIÓN DEL CÁNCER Transformando la información en acciones para una mejor salud EN LA POBLACIÓN ADULTA ATENDIDA EN EL SGSSS DE COLOMBIA 2021. Available from: https://cuentadealtocosto.org/site/wp-content/uploads/2022/08/01_agosto_libro_cancer_2021_final.pdfTest; Divi-Sion Of Hematology KS. From the Division of Hematology/Oncology. Mayo Clin Proc n April [Internet]. 2013 [cited 2022 Dec 25];88(4):360–76. Available from: http://dxTest.; D’agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, et al. Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. Journal of Clinical Oncology. 2022 May 1;364.; Avet-Loiseau H, Durie BGM, Cavo M, Attal M, Gutierrez N, Haessler J, et al. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia 2013 27:3 [Internet]. 2012 Oct 3 [cited 2023 Jan 1];27(3):711–7. Available from: https://www-nature-com.aure.unab.edu.co/articles/leu2012282Test; Hari PN, Zhang MJ, Roy V, Pérez WS, Bashey A, To LB, et al. Is the international staging system superior to the Durie–Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. Leukemia 2009 23:8 [Internet]. 2009 Mar 26 [cited 2023 Jan 20];23(8):1528–34. Available from: https://www-nature-com.aure.unab.edu.co/articles/leu200961Test; Overview %7C Myeloma: diagnosis and management %7C Guidance %7C NICE [Internet]. [cited 2023 Jan 23]. Available from: https://www.nice.org.uk/guidance/ng35Test; Sive J, Cuthill K, Hunter H, Kazmi M, Pratt G, Smith D. Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline. Br J Haematol. 2021 Apr 1;193(2):245–68.; Mikhael J, Ismaila N, Cheung MC, Costello C, Dhodapkar M V., Kumar S, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. Journal of Clinical Oncology. 2019 Apr 1;37(14):1228–63.; Colombiana de Hematología Oncología -ACHO A. Guía de Práctica Clínica para el tratamiento del mieloma múltiple.; Pessoa de Magalhães Filho RJ, Crusoe E, Riva E, Bujan W, Conte G, Navarro Cabrera JR, et al. Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American Countries. Clin Lymphoma Myeloma Leuk. 2019 Jan 1;19(1):e43–50.; Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: A report from international myeloma working group. Journal of Clinical Oncology. 2015 Aug 3;33(26):2863–9.; Greipp PR, Miguel JS, Dune BGM, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. Journal of Clinical Oncology. 2005 Sep 21;23(15):3412–20.; Hungria VTM, Maiolino A, Martinez G, Colleoni G, Oliveira L, Coelho EOM, et al. Validation of International Staging System (ISS) for Multiple Myeloma: A Retrospective Analysis of 487 Patients at 8 Brazilian Centers. Blood. 2005 Nov 16;106(11):5069.; D’Agostino M, Waage A, Lahuerta JJ, Bertsch U, Zamagni E, Bullinger L, et al. Validation and Improvement Opportunities of the Revised International Staging System for Multiple Myeloma: An Analysis on Mature Data from European Clinical Trials within the Harmony Big Data Platform. Blood. 2019 Nov 13;134(Supplement_1):1773.; Kent P, Cancelliere C, Boyle E, Cassidy JD, Kongsted A. A conceptual framework for prognostic research. [cited 2023 Feb 21]; Available from: https://doi.org/10.1186/s12874-020-01050-7Test; RENEHOC - ACHO [Internet]. [cited 2023 Jan 23]. Available from: https://acho.com.co/renehocTest/; Abello V, Mantilla WA, Idrobo H, Sossa CL, Salazar LA, Pena A, et al. Real-World Evidence of Epidemiology and Clinical Outcomes in Multiple Myeloma, Findings from the Registry of Hemato-Oncologic Malignancies in Colombia, Observational Study. Clin Lymphoma Myeloma Leuk. 2022 Jun 1;22(6):e405–13.; Huang J, Chan SC, S Wong MC, Huang J, Chai Chan S, Lok V, et al. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Articles Lancet Haematol [Internet]. 2022 [cited 2023 Jan 11];9:670–7. Available from: www.thelancet.com/haematology; Landgren O, Weiss BM. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia 2009 23:10 [Internet]. 2009 Jul 9 [cited 2023 Jan 11];23(10):1691–7. Available from: https://www-nature-com.aure.unab.edu.co/articles/leu2009134Test; Abello V, Mantilla WA, Idrobo H, Sossa CL, Salazar LA, Pena A, et al. Real-World Evidence of Epidemiology and Clinical Outcomes in Multiple Myeloma, Findings from the Registry of Hemato-Oncologic Malignancies in Colombia, Observational Study. Clin Lymphoma Myeloma Leuk [Internet]. 2022 Jun 1 [cited 2023 Jan 22];22(6):e405–13. Available from: http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152265021024782/fulltextTest; Combariza JF, Ordúz R, Agudelo C, Hernandez S, Madera AM, León G, et al. Incidence and Prognostic Significance of High-Risk Cytogenetically Abnormalities in Multiple Myeloma Patients in Colombia. Clin Lymphoma Myeloma Leuk. 2022 Aug 1;22(8):601–7.; Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK, et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, UK [Internet]. 2009 [cited 2023 Jan 15];23(12):2210. Available from: /pmc/articles/PMC2964268/; Ribatti D. A historical perspective on milestones in multiple myeloma research. Eur J Haematol [Internet]. 2018 Mar 1 [cited 2023 Jan 17];100(3):221–8. Available from: https://pubmed.ncbi.nlm.nih.gov/29194778Test/; Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia [Internet]. 2014 [cited 2023 Jan 17];28(5):1122. Available from: /pmc/articles/PMC4000285/; Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, et al. Management of newly diagnosed symptomatic multiple myeloma: Updated mayo stratification of myeloma and risk-adapted therapy (msmart) consensus guidelines 2013. Mayo Clin Proc [Internet]. 2013 Apr 1 [cited 2023 Jan 15];88(4):360–76. Available from: http://www.mayoclinicproceedings.org/article/S0025619613000773/fulltextTest; Rajan AM, Rajkumar S V. Interpretation of cytogenetic results in multiple myeloma for clinical practice. Blood Cancer J [Internet]. 2015 Oct 30 [cited 2023 Jan 17];5(10). Available from: https://pubmed.ncbi.nlm.nih.gov/26517360Test/; Legües ME, Morales P, Valenzuela M, Encina A, Martí MJ, Bascuñán C, et al. Características citogenéticas y detección de anormalidades de alto riesgo en mieloma múltiple. Rev Med Chil [Internet]. 2019 [cited 2023 Jan 17];147(1):61–4. Available from: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000100061&lng=es&nrm=iso&tlng=esTest; Rosiñ ol L, Oriol A, Isabel Teruel A, Herná ndez D, Ló pez-Jimé nez J, de la Rubia J, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. 2012 [cited 2023 Jan 15]; Available from: http://ashpublications.org/blood/article-pdf/120/8/1589/1498997/zh803412001589.pdfTest; Durie BGM, Hoering A, Sexton R, Abidi MH, Epstein J, Rajkumar SV, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J [Internet]. 2020 [cited 2023 Jan 15];10:53. Available from: https://doi.org/10.1038/s41408-020-0311-8Test; Devarakonda S, Efebera Y, Sharma N. cancers Role of Stem Cell Transplantation in Multiple Myeloma. 2021 [cited 2023 Jan 18]; Available from: https://doi.org/10.3390/cancers13040863Test; Gay F, Oliva S, Magarotto V, Bs M, Ma S, Omedè P, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol [Internet]. 2015 [cited 2023 Jan 18];16:1617–46. Available from: www.thelancet.com/oncology; Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med [Internet]. 2017 Apr 6 [cited 2023 Jan 17];376(14):1311–20. Available from: https://pubmed.ncbi.nlm.nih.gov/28379796Test/; Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US intergroup trial S9321. Journal of Clinical Oncology. 2006 Feb 20;24(6):929–36.; Perrot A, Lauwers-Cances V, Cazaubiel T, Facon T, Caillot D, Clement-Filliatre L, et al. Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial. Blood [Internet]. 2020 Nov 5 [cited 2023 Jan 18];136(Supplement 1):39–39. Available from: https://ashpublications.org/blood/article/136/SupplementTest 1/39/470028/Early-Versus-Late-Autologous-Stem-Cell-Transplant; Merlini G, Waldenstrom JG, Jayakar SD. A New Improved Clinical Staging System for Multiple Myeloma Based on Analysis of 123 Treated Patients. Blood. 1980 Jun 1;55(6):1011–9.; Jacobson JL, Hussein MA, Barlogie B, Durie BGM, Crowley JJ. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol. 2003 Aug;122(3):441–50.; Abdallah NH, Binder M, Rajkumar SV, Greipp PT, Kapoor P, Dispenzieri A, et al. ARTICLE OPEN A simple additive staging system for newly diagnosed multiple myeloma. [cited 2023 Apr 3]; Available from: https://doi.org/10.1038/s41408-022-00611-xTest; Terebelo HR, Abonour R, Gasparetto CJ, Toomey K, Durie BGM, Hardin JW, et al. Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry. Br J Haematol. 2019 Dec 1;187(5):602–14.; Norman G, Streiner D. Biostatistics - The bare essentials. 4th edition. Mehta Linda, editor. People’s Medical Publishing House-USA; 2014.; Ma Argimon Pallás J, Jiménez Villa J. Métodos de investigación clínica y epidemiológica 5.a EDICIÓN.; Carolina Alba A, Agoritsas T, Walsh M, Hanna S, Iorio A, Devereaux PJ, et al. Users’ Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3rd ed.; Royston P, Altman DG. External validation of a Cox prognostic model: principles and methods [Internet]. Vol. 13, Medical Research Methodology. 2013. Available from: http://www.biomedcentral.com/1471-2288/13/33Test; Abello V, Idrobo H, Sossa CL, Galvez KM, Saavedra D, Solano MH, et al. The Status of Multiple Myeloma in Colombia: First Report of the Colombian Registry for Hemato-Oncological Diseases (RENEHOC). Asociacion Colombiana De Hematologia y Oncologia (ACHO). Blood [Internet]. 2018 Nov 29 [cited 2023 Jan 22];132(Supplement 1):5597–5597. Available from: https://ashpublications.org/blood/article/132/SupplementTest 1/5597/263281/The-Status-of-Multiple-Myeloma-in-Colombia-First; Redder L, Klausen TW, Vangsted AJ, Gregersen H, Andersen NF, Pedersen RS, et al. Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population-based study from the Danish national multiple myeloma registry. Br J Haematol. 2021 Apr 1;193(1):119–24.; Cook G, Royle KL, Pawlyn C, Hockaday A, Shah V, Kaiser MF, et al. A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. Lancet Haematol [Internet]. 2019 Mar 1 [cited 2023 Sep 5];6(3):e154. Available from: /pmc/articles/PMC6391517/; http://hdl.handle.net/20.500.12749/22620Test; instname:Universidad Autónoma de Bucaramanga - UNAB; reponame:Repositorio Institucional UNAB; repourl:https://repository.unab.edu.coTest |
| الإتاحة: | https://doi.org/20.500.12749/22620Test https://doi.org/10.1186/s12874-020-01050-7Test https://doi.org/10.1038/s41408-020-0311-8Test https://doi.org/10.3390/cancers13040863Test https://doi.org/10.1038/s41408-022-00611-xTest https://hdl.handle.net/20.500.12749/22620Test |
| حقوق: | http://creativecommons.org/licenses/by-nc-nd/2.5/coTest/ ; Abierto (Texto Completo) ; info:eu-repo/semantics/openAccess ; Atribución-NoComercial-SinDerivadas 2.5 Colombia |
| رقم الانضمام: | edsbas.4FFC7C7E |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |